Literature DB >> 6275278

The electrophysiological basis of the bradycardic action of AQA 39 on the sinoatrial node.

W Osterrieder, D Pelzer, Q F Yang, W Trautwein.   

Abstract

The electrophysiological effects of the bradycardic agent AQA 39 (5,6-dimethoxy-2-[3-[[ alpha-(3,4-dimethoxy) phenylethyl] methylamino] propyl] phthalimidine hydrochloride) on small preparations of the S-A node of the rabbit heart were investigated. The following results were obtained: 1. The decrease in the rate of the spontaneous preparation resulted from a lower rate of diastolic depolarization, a slower upstroke and a longer duration of the action potential. Concomitantly, overshoot and maximum diastolic potential were decreased. 2. The drug effect on rate strongly depended on the potential during diastole. AQA 39 acted stronger the more positive the maximum diastolic potential. 3. In voltage-clamp experiments, the membrane potential was held at -40 mV and transiently depolarized by square pulses to -10 mV. At a low pulsing rate (0.005 Hz), the main effect was a reduction of the time-dependent potassium current (Ik); the slow inward current (Isi) was only slightly reduced. However, when the pulsing rate was increased to 1 Hz, a clear reduction of Isi was observed. 4. When the block of Ca channels had reached a steady state during continuous pulsing in the presence of the drug, part of the block could be removed by rest periods, relief of block being dependent on the membrane potential during rest. At a fixed rest period of 45s, relief of block was nearly complete for potentials negative to -55 mV but negligible positive to -35mV. 5. AQA 39 shifted the dose-response curve to ionophoretic application of acetylcholine to higher concentrations, suggesting a competitive action of the drug with acetylcholine at the muscarinic receptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6275278     DOI: 10.1007/bf00503823

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

Review 1.  Muscarinic acetylcholine receptor.

Authors:  E Heilbronn; T Bartfai
Journal:  Prog Neurobiol       Date:  1978       Impact factor: 11.685

2.  Membrane currents in the rabbit sinoatrial node cell as studied by the double microelectrode method.

Authors:  A Noma; H Irisawa
Journal:  Pflugers Arch       Date:  1976-06-29       Impact factor: 3.657

3.  Membrane currents underlying activity in frog sinus venosus.

Authors:  H F Brown; W Giles; S J Noble
Journal:  J Physiol       Date:  1977-10       Impact factor: 5.182

4.  Relaxation of the ACh-induced potassium current in the rabbit sinoatrial node cell.

Authors:  A Noma; W Trautwein
Journal:  Pflugers Arch       Date:  1978-11-30       Impact factor: 3.657

5.  AQA 39*, a new bradycardic agent which blocks myocardial calcium (Ca) channels in a frequency- and voltage-dependent manner.

Authors:  W Trautwein; D Pelzer; T F McDonald; W Osterrieder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-11       Impact factor: 3.000

6.  The time course of the muscarinic response to ionophoretic acetylcholine application to the S-A node of the rabbit heart.

Authors:  W Osterrieder; Q F Yang; W Trautwein
Journal:  Pflugers Arch       Date:  1981-03       Impact factor: 3.657

7.  On the mechanism of slow calcium channel block in heart.

Authors:  T F McDonald; D Pelzer; W Trautwein
Journal:  Pflugers Arch       Date:  1980-05       Impact factor: 3.657

8.  Slow inward current and its role mediating the chronotropic effect of epinephrine in the rabbit sinoatrial node.

Authors:  A Noma; H Kotake; H Irisawa
Journal:  Pflugers Arch       Date:  1980-10       Impact factor: 3.657

9.  Effect of hypoxia on the sinoatrial node, atrium, and atrioventricular node in the rabbit heart.

Authors:  J Senges; T Mizutani; D Pelzer; J Brachmann; U Sonnhof; W Kübler
Journal:  Circ Res       Date:  1979-06       Impact factor: 17.367

  9 in total
  9 in total

1.  Cat ventricular muscle treated with D600: characteristics of calcium channel block and unblock.

Authors:  T F McDonald; D Pelzer; W Trautwein
Journal:  J Physiol       Date:  1984-07       Impact factor: 5.182

2.  AQA 39*, a new bradycardic agent which blocks myocardial calcium (Ca) channels in a frequency- and voltage-dependent manner.

Authors:  W Trautwein; D Pelzer; T F McDonald; W Osterrieder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-11       Impact factor: 3.000

3.  Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration.

Authors:  C Lillie; W Kobinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-12       Impact factor: 3.000

4.  Elementary currents through Ca2+ channels in guinea pig myocytes.

Authors:  A Cavalié; R Ochi; D Pelzer; W Trautwein
Journal:  Pflugers Arch       Date:  1983-09       Impact factor: 3.657

5.  On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49.

Authors:  T Doerr; W Trautwein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

6.  Inhibition of potassium outward currents and pacemaker current in sheep cardiac Purkinje fibres by the verapamil derivative YS 035.

Authors:  F Berger; U Borchard; D Hafner; T Kammer; T Weis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

7.  Investigations differentiating the mechanism of specific bradycardic agents from that of calcium channel blockers.

Authors:  C Lillie; W Kobinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

Review 8.  Channel-mediated calcium current in the heart.

Authors:  W A Coetzee
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Authors:  M Holck; W Osterrieder
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.